Contrasting ProSomnus (OSA) and Its Competitors

ProSomnus (NASDAQ:OSA) is one of 143 publicly-traded companies in the “Medical Devices” industry, but how does it compare to its competitors? We will compare ProSomnus to related businesses based on the strength of its earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Volatility & Risk

ProSomnus has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, ProSomnus’ competitors have a beta of 0.86, meaning that their average share price is 14% less volatile than the S&P 500.

Profitability

This table compares ProSomnus and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProSomnus	-87.14%	N/A	-106.30%
ProSomnus Competitors	-79.10%	-63.90%	-21.64%

Earnings & Valuation

This table compares ProSomnus and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ProSomnus	$27.65 million	-$24.09 million	-0.34
ProSomnus Competitors	$471.36 million	$14.70 million	90.69

ProSomnus’ competitors have higher revenue and earnings than ProSomnus. ProSomnus is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings for ProSomnus and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProSomnus	0	1	3	0	2.75
ProSomnus Competitors	308	1137	1352	40	2.40

ProSomnus currently has a consensus target price of $2.33, indicating a potential upside of 345.38%. As a group, “Medical Devices” companies have a potential upside of 47.78%. Given ProSomnus’ stronger consensus rating and higher possible upside, equities research analysts plainly believe ProSomnus is more favorable than its competitors.

Institutional & Insider Ownership

70.0% of ProSomnus shares are held by institutional investors. Comparatively, 26.4% of shares of all “Medical Devices” companies are held by institutional investors. 7.7% of ProSomnus shares are held by insiders. Comparatively, 24.2% of shares of all “Medical Devices” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ProSomnus competitors beat ProSomnus on 8 of the 13 factors compared.

ProSomnus Company Profile

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.